FITC-dextran is typically injected intravenously when studying blood-brain barrier (BBB) permeability. Some of these studies include:
1. Blood-brain barrier integrity in a mouse model of Alzheimer’s disease with or without acute 3D6 immunotherapy: This study explores the administration of 4 kDa FITC-dextran to assess BBB permeability in an Alzheimer’s disease model.
2. High and low molecular weight fluorescein isothiocyanate (FITC)–dextrans to assess blood-brain barrier disruption: Technical considerations: A technical examination of using FITC-dextran for assessing BBB disruption.
3. Radiation-induced permeability and leukocyte adhesion in the rat blood–brain barrier: Modulation with anti-ICAM-1 antibodies: This article investigates radiation-induced changes in BBB permeability, employing FITC-dextran as a tracer.
4. Modulation of blood-brain barrier permeability by neutrophils: In vitro and in vivo studies: Research exploring how neutrophils affect BBB permeability, using 4 kDa FITC-dextran.
5. Differential effects of hydrocortisone and TNFα on tight junction proteins in an in vitro model of the human blood-brain barrier: This paper assesses how tight junction proteins affect BBB permeability using FITC-dextran. For accurate results, intravenous administration is generally recommended for BBB studies.
However, there are studies that have used oral administration to assess BBB permeability. Some of these studies include:
1. Changes in brain kynurenine levels via gut microbiota and gut-barrier disruption induced by chronic ethanol exposure in mice: This study shows FITC-dextran 4 kDa in plasma after oral administration, highlighting gut-barrier disruption.
2. Oral Administration of Lactobacillus Inhibits the Permeability of Blood‐Brain and Gut Barriers in a Parkinsonism Model: This study assesses the effects of oral administration of FITC-dextran 4 kDa on BBB permeability in a Parkinsonism model.
3. Assessment of gut barrier integrity in mice using fluorescein-isothiocyanate-labeled dextran: This paper describes FITC-dextran 4 kDa administered orally to examine permeability in gut barrier models, which may extend to BBB studies.